Latest stories on MLTX
MoonLake Immunotherapeutics reports Q3 EPS (93c), consensus (78c)
The Fly38 · neutralearnings
MoonLake Immunotherapeutics GAAP EPS of -$0.93 misses by $0.15
Business Insider34 · bearishearnings
MoonLake Immunotherapeutics (MLTX) files 8-K
SEC 8-K50 · neutralgeneral
MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update
Business Insider58 · neutralearnings
MoonLake: Downgrading To Hold As FDA Priority Review Decision Remains
Seeking Alpha42 · neutralanalyst
MoonLake’s sonelokimab faces regulatory, commercial tests, RBC says
Seeking Alpha44 · neutralanalyst
MoonLake Immunotherapeutics submits sonelokimab BLA
Seeking Alpha71 · bullishproduct/pr
MoonLake Immunotherapeutics (MLTX) files 8-K
SEC 8-K50 · neutralgeneral
Cantor Fitzgerald reiterates Moonlake stock rating at Overweight
Investing.com Analyst Ratings61 · neutralanalyst
MLTX Stock On Track For Worst Week Since Last Fall As FDA Filing Date For Skin Disease Drug Draws Near
Stocktwits News28 · bearishgeneral
MoonLake Immunotherapeutics: The Bull Case Does Not Require Clinical Supremacy
Seeking Alpha63 · neutralproduct/pr
MoonLake’s Psoriatic Arthritis Drug Shows Promise In Phase 3 Trial – Retail Shrugs Off Premarket Slide, Says ‘Pipeline Is Intact’
Stocktwits News67 · bullishproduct/pr
Sonelokimab Delivers Broad Efficacy in Phase 3 Psoriatic Arthritis Trial: MoonLake Bolstered by Solid Cash Position
August 10, 2026
MarketChameleon73 · bullishproduct/pr
Moonlake Shares Drop 11 Pre Market After Q2 Earnings Phase 3 Trial Results
The Fly32 · bearishearnings
MoonLake Immunotherapeutics reports Q2 EPS (84c), consensus (90c)
The Fly38 · neutralearnings
MoonLake says Phase 3 IZAR-1 trial met all clinical endpoints at Week 16
The Fly73 · bullishproduct/pr
Why is MoonLake Immunotherapeutics stock plunging today?
Investing.com Markets32 · bearishgeneral
MoonLake Immunotherapeutics (MLTX) files 8-K
SEC 8-K50 · neutralgeneral
MoonLake Immunotherapeutics GAAP EPS of -$0.84
Seeking Alpha34 · bearishearnings
MLTX Stock Under Pressure As Investors Await Psoriatic Arthritis Trial Data
Stocktwits News38 · neutralgeneral
H.C. Wainwright reiterates Moonlake stock buy rating on funding
Investing.com Analyst Ratings61 · neutralanalyst
SLS Vs MLTX: Retail Traders Race To Pick Merck’s Next Biotech Buyout As Keytruda’s $31.7B Patent Cliff Nears
Stocktwits News58 · neutralgeneral
MoonLake Immunotherapeutics' CFO Sells 39K Shares
The Motley Fool42 · neutralgeneral